5-hydroxymethylomeprazole has been researched along with bupropion in 1 studies
*Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. [MeSH]
*Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. [MeSH]
| Studies (5-hydroxymethylomeprazole) | Trials (5-hydroxymethylomeprazole) | Recent Studies (post-2010) (5-hydroxymethylomeprazole) | Studies (bupropion) | Trials (bupropion) | Recent Studies (post-2010) (bupropion) |
|---|---|---|---|---|---|
| 54 | 17 | 15 | 3,392 | 755 | 1,329 |
| Protein | Taxonomy | 5-hydroxymethylomeprazole (IC50) | bupropion (IC50) |
|---|---|---|---|
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | 5.2693 | |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | 5.2693 | |
| Integrin alpha-5 | Homo sapiens (human) | 1.8 | |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | 5.2693 | |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | 0.9373 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.2003 | |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | 1.2028 | |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | 1.367 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1.9983 | |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | 7.9 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | 0.0135 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.0848 | |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | 5.2693 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dinger, J; Maurer, HH; Meyer, MR | 1 |
1 other study(ies) available for 5-hydroxymethylomeprazole and bupropion
| Article | Year |
|---|---|
Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bupropion; Calibration; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Evaluation, Preclinical; Humans; Substrate Specificity; Tandem Mass Spectrometry; Umbelliferones | 2014 |